ATYR1923 Uses, Dosage, Side Effects and more

ATYR1923 is a fusion protein comprised of the immuno-modulatory domain of histidyl tRNA synthetase fused to the FC region of a human antibody. It is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory disease states.

Trade Name ATYR1923
Generic ATYR1923
Type
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: January 7, 2025 at 1:49 am

How ATYR1923 works

ATYR1923 acts to reduce overall inflammation and fibrotic deposition in the lungs, stabilizing its function; it acts as a disease modifying therapy for people with interstitial lung disease (ILD). The mechanism behind this is that the drug selectively binds to and regulates NRP2, reducing its innate and adaptive immune response pathways associated with cytokine and chemokine production and T-cell activation.

Innovators Monograph


*** Taking medicines without doctor's advice can cause long-term problems.
Share